Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$71.71 USD
+0.19 (0.27%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $71.76 +0.05 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Axsome Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 271 | 50 | 0 | 0 | 0 |
Cost Of Goods | 26 | 5 | 0 | 0 | 0 |
Gross Profit | 245 | 45 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 476 | 225 | 125 | 99 | 67 |
Income After Depreciation & Amortization | -232 | -180 | -125 | -99 | -67 |
Non-Operating Income | 0 | 0 | 0 | -1 | 0 |
Interest Expense | 6 | 7 | 6 | 3 | 1 |
Pretax Income | -238 | -187 | -130 | -103 | -68 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -239 | -187 | -130 | -103 | -68 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -239 | -187 | -130 | -103 | -68 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -222 | -173 | -122 | -98 | -67 |
Depreciation & Amortization (Cash Flow) | 9 | 7 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -232 | -180 | -125 | -99 | -67 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.43 | 40.67 | 37.62 | 37.21 | 34.02 |
Diluted EPS Before Non-Recurring Items | -2.67 | -4.42 | -3.47 | -2.74 | -2.01 |
Diluted Net EPS (GAAP) | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 |
Fiscal Year end for Axsome Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 71.53 | 57.79 | 46.70 | 94.58 |
Cost Of Goods | NA | 7.38 | 6.53 | 4.60 | 7.56 |
Gross Profit | NA | 64.15 | 51.26 | 42.10 | 87.02 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 162.43 | 113.39 | 107.16 | 93.39 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -98.28 | -62.13 | -65.06 | -6.37 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 0.70 | 0.76 | 2.73 | 2.26 |
Pretax Income | NA | -98.98 | -62.88 | -67.79 | -8.64 |
Income Taxes | NA | -0.32 | -0.68 | -0.62 | 2.58 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -98.65 | -62.20 | -67.17 | -11.22 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -98.65 | -62.20 | -67.17 | -11.22 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 47.33 | 47.12 | 43.67 | 43.52 |
Diluted EPS Before Non-Recurring Items | NA | -0.73 | -1.32 | -1.00 | -0.22 |
Diluted Net EPS (GAAP) | NA | -2.15 | -1.32 | -1.54 | -0.26 |